Pfizer’s US$17 B Buyout of Hospira Paves the Way for a Split

By Heather Cartwright

Pharma Deals Review: Vol 2015 Issue 2 (Table of Contents)

Published: 28 Feb-2015

DOI: 10.3833/pdr.v2015.i2.2093     ISSN: 1756-7874

Section: Mergers & Acquisitions



Signalling its intent to spin off its global established products(GEP) division in 2017, Pfizer has agreed to acquire Hospira, the market leader in the generic injectables segment, in a deal that values the company at approximately US$17 B inclusive of net debt...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details